Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

rials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of Micromet's product candidate
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today announced a litigation update. ... Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in ... of Virginia , the Court issued ... key claims in favor of the Defendants on the ...
(Date:7/1/2015)... and PARIS , July ... and Genective, key developer of biotech crops, today ... of new generations of insect control traits. ... to counter the realities of advancing insect resistance. ... AgBiome,s unique insect control technology with Genective,s capability ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical ... new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. ... that will increase healthcare worker safety and reduce financial costs. , CTI Electronics ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... July 17 Encorium Group, Inc. (Nasdaq: ... research organization (CRO) that provides design, development, and management ... of the world,s leading pharmaceutical companies, today announced that ... Company,s U.S. business to Pierrel Research USA, Inc., a ...
... 16 Nile Therapeutics, Inc. (Nasdaq: NLTX ), a ... patients, today announced that it has completed a private placement of ... stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital ... agent for the transaction. , , ...
... - Introductory Webinar, July 21st, 11am EDT, ... September 15-16, San Diego,CA , ChemAxon, a ... Excel. The add-in for Microsoft Excel(R),brings all of the capabilities and ... will be introduced at a free webinar,on July 21st and Workshop ...
Cached Biology Technology:Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 3Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 4Nile Therapeutics, Inc. Completes $3.4 Million Private Placement 2Nile Therapeutics, Inc. Completes $3.4 Million Private Placement 3ChemAxon Launches JChem for Excel 2
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/26/2015)... Utah , June 26, 2015 ATL Technology, ... and devices with specialties in single use solutions, headquartered in ... of MedConx, Inc. (a California corporation ... and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility ...
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... Ecosystem ecologist Ann Bartuska will give a free public lecture ... managers are doing to respond to climate change and to ... lecture, titled "Climate Change, Bark Beetles, Environmental Markets and Sustainability: ... place at 4:10 p.m., April 5, in Bourns Hall ...
... that prenatal health care professionals are concerned about patients, ... effective counseling. Rates of excessive weight gain during ... health outcomes for mothers and children, have increased in ... providers agree that weight gain is an important topic ...
... Iowa USA - A leading scientific journal in Pakistan, ... ,* recently published a paper titled "A New ... Ancient Approach to Peace," indicating that the military application ... discusses how militaries worldwide could use the Transcendental Meditation ...
Cached Biology News:UC Riverside lecture: Climate change, bark beetles, environmental markets and sustainability 2Prenatal health-care providers inconsistent in weight-gain counseling 2Military application of Transcendental Meditation gaining acceptance 2Military application of Transcendental Meditation gaining acceptance 3Military application of Transcendental Meditation gaining acceptance 4
... 1 kit. Facilitates the simple, phenol-free extraction ... hard tissue requiring proteinase K digestion.Each kit ... from 50 preparations of up to 25 ... & Purification, Purification and Amplification of Genomic ...
Request Info...
Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Biology Products: